

RECEIVED
CENTRAL FAX CENTERHAMRE, SCHUMANN, NOV 27 2007
MUELLER & LARSON, P.C.

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION November 27, 2007

TO: Mail Stop: AMENDMENT
Examiner: A. GUSSOW
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FROM: Bryan A. Wong

OUR REF: 09548.1019USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 11


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: AMENDMENT UNDER 37 C.F.R. §1.111 (10 pages)

Applicant: SUN
Serial No.: 10/571836
App. Filed: March 15, 2006
Group Art No.: 1643

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Bryan A. Wong
Reg. No.: 50,836

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Tracy Kimmel

Signature 

Date

NOV. 27, 2007

225 SOUTH SIXTH STREET · SUITE 2650 · MINNEAPOLIS · MN 55402
TEL 612.455.3800 · FAX 612.455.3801
WWW.HSML.COM · MAIL@HSML.COM

RECEIVED
CENTRAL FAX CENTER

NOV 27 2007

S/N 10/571,836

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SUN	Examiner:	A. GUSSOW
Serial No.:	10/571,836	Group Art Unit:	1643
Filed:	March 15, 2006	Docket No.:	09548.1019USWO
Title:	A SUPERANTIGEN FUSION PROTEIN FOR ANTI-CANCER THERAPY AND METHODS FOR THE PRODUCTION THEREOF (AS AMENDED)		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on November 27, 2007.

By: 

Name: Tracy Khamel

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.111

Dear Commissioner:

In response to the non-final Office Action mailed August 27, 2007, please amend the above-identified application as indicated herein.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper and a Listing of Claims is provided.

Remarks begin on page 7 of this paper.